2026-10-14T13:12:11Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33966818 2026-09-22T17:24:21Z category_12 category_15 category_19 category_21 category_734 category_64 category_106 category_122 portal_5 item_type_3 month_year_09_2026

<p>Baseline characteristics of the study population.</p> Janosch W. Kratz (25091120) Renata Voltolini Velho (7889282) Sandra Bock (25091123) Jalid Sehouli (60337) Sylvia Mechsner (3534656) Cell Biology Neuroscience Pharmacology Biotechnology Biological Sciences not elsewhere classified Cancer Science Policy Mental Health severity score 1 g ., tramadol g ., ibuprofen emerging evidence indicates effective adjunct therapy based medicinal products 0004 ), accompanied chronic pain conditions chronic pelvic pain xlink "> endometriosis 0013 ), anxiety 0 &# 8211 0001 ), disability month treatment period 0001 ), chronic pain one month persistent pain pain intensity pain episodes pain days managing pain well tolerated titration phase three months significant improvements short follow related symptoms predominantly mild placebo control opioid analgesics occurring mainly improved significantly declining thereafter csi ). continued benefit central sensitization center design cbd ratio balanced thc analgesic use although limited 45 years 27 completed 001 ). <div><p>Endometriosis is a chronic gynecological disorder characterized by persistent pain and impaired quality of life, with limited effective treatment options. Emerging evidence indicates that cannabinoids may provide analgesic and symptom-relieving effects in chronic pain conditions. This prospective single-center cohort study investigated the effects of standardized oral cannabis extracts (cannabinoid-based medicinal products, CBMPs) on pain and quality of life in women with endometriosis. Thirty premenopausal women aged 18–45 years with confirmed endometriosis and chronic pelvic pain were enrolled; 27 completed the 3-month treatment period. Participants received oral CBMPs containing a balanced THC: CBD ratio. Pain intensity, frequency of pain episodes, analgesic use, fatigue, anxiety, central sensitization, disability, and quality of life were assessed using validated questionnaires (VAS, EHP-30, PDI, CFS, GAD-7, CSI). Significant improvements were observed after one month of treatment, with continued benefit over three months. Pain intensity decreased markedly (p = 0.0004), accompanied by reductions in the number of pain days and analgesic use, including both NSAIDs (e.g., ibuprofen, diclofenac) and opioid analgesics (e.g., tramadol, tilidin, oxycodone) (p < 0.001). Fatigue (p = 0.0013), anxiety (p < 0.0001), central sensitization (p < 0.0001), disability (p < 0.0001), and overall quality of life (EHP-30) improved significantly. Treatment was well tolerated; side effects were predominantly mild (severity score 1 on a 0–3 scale) and transient, occurring mainly during the titration phase and declining thereafter. Although limited by its single-center design, lack of placebo control, and short follow-up, this study provides preliminary evidence that oral CBMPs may represent a safe and effective adjunct therapy for managing pain and related symptoms in women with endometriosis. Larger randomized controlled trials are warranted to confirm these findings and establish optimal dosing strategies.</p></div> 2026-09-22T17:24:11Z Dataset Dataset 10.1371/journal.pone.0356768.t001 https://figshare.com/articles/dataset/_p_Baseline_characteristics_of_the_study_population_p_/33966818 CC BY 4.0